Press Releases

Exelixis, Inc. announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences.  Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20...

Sucampo Pharmaceuticals, Inc. an international pharmaceutical company, and Numab AG today announced that Sucampo’s wholly owned subsidiary, Sucampo AG, and Numab AG, have entered into a research and development collaboration that provides Sucampo with access to Numab’s proprietary...

Marseille France, September 8, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment in the...

Physicians are highly engaged with social media for both personal and professional use, according to a 4,033-clinician study authored and conducted by QuantiaMD, the largest mobile and online physician community, and Care Continuum Alliance, an international association for...

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening...

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13 at 11:15 a.m. (ET) in New York. About Synta...

Hybrigenics, a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases, announces today that AFSSAPS, the French drug agency, has granted authorization for a Phase II clinical...